UNSPSC 51341800: Antiviral amides

Antiviral drugs made from organic compounds containing the -CO-NH2 radical, derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group.

UNSPSC 51341800 Antiviral amides, a Class code, encompasses pharmaceutical products and medical supplies procured by state and local health agencies, emergency services, and cooperative purchasing organizations. Recent solicitations under this code reveal state and local buyers acquiring naloxone and drug deactivation systems for community health support, generic pharmaceuticals and over-the-counter products through multi-state cooperative agreements, and medical and first aid supplies for fire rescue operations. The issuing bodies include county health departments (Seminole County, Florida), municipal fire departments and purchasing offices (City of Tampa), state health and human services agencies (Texas HHS Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). These jurisdictions procure through competitive sealed-bid processes, RFPs, and RFIs that require vendors to meet cGMP and Drug Supply Chain Security Act compliance, maintain specified insurance coverage, and demonstrate pricing flexibility through various net-price or WAC-minus structures.

Recent activity concentrates in Florida, Texas, and Minnesota, with multi-state cooperative vehicles expanding reach across the upper Midwest and beyond. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response due July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, with an estimated contract value of $700,000 and response due March 13, 2026, designated as a sheltered market opportunity with a 5 percent bid discount for certified Small Local Business Enterprises; the Texas HHS Commission's RFI for direct-to-manufacturer prescription program capabilities (response due April 3, 2026); and the Minnesota MMCAP's RFP to establish multiple contracts for generic pharmaceuticals and OTC products across participating jurisdictions, with proposals due March 26, 2026. Vendors must supply through authorized wholesalers where specified and comply with quarterly or annual delivery schedules, with contract terms typically ranging from one to two years with optional renewals.